Ratings for Biomarin Pharmaceutical BMRN were provided by 8 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 6 | 1 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 1 | 0 | 0 | 0 | 0 |
| 3M Ago | 0 | 5 | 1 | 0 | 0 |
Analysts have recently evaluated Biomarin Pharmaceutical and provided 12-month price targets. The average target is $106.0, accompanied by a high estimate of $117.00 and a low estimate of $100.00. Highlighting a 9.95% decrease, the current average has fallen from the previous average price target of $117.71.
Analyzing Analyst Ratings: A Detailed Breakdown
The perception of Biomarin Pharmaceutical by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Joel Beatty | Baird | Lowers | Outperform | $104.00 | $127.00 |
| Paul Matteis | Stifel | Maintains | Buy | $101.00 | - |
| Luca Issi | RBC Capital | Maintains | Sector Perform | $100.00 | $100.00 |
| Kostas Biliouris | BMO Capital | Lowers | Outperform | $100.00 | $102.00 |
| Christopher Raymond | Piper Sandler | Lowers | Overweight | $115.00 | $125.00 |
| Matthew Harrison | Morgan Stanley | Lowers | Overweight | $117.00 | $125.00 |
| Gena Wang | Barclays | Lowers | Overweight | $111.00 | $125.00 |
| Olivia Brayer | Cantor Fitzgerald | Lowers | Overweight | $100.00 | $120.00 |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Biomarin Pharmaceutical. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Biomarin Pharmaceutical compared to the broader market.
- Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Biomarin Pharmaceutical's stock. This examination reveals shifts in analysts' expectations over time.
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Biomarin Pharmaceutical's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on Biomarin Pharmaceutical analyst ratings.
Unveiling the Story Behind Biomarin Pharmaceutical
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the U.S. in 2023.
Biomarin Pharmaceutical's Economic Impact: An Analysis
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Positive Revenue Trend: Examining Biomarin Pharmaceutical's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 15.04% as of 30 September, 2023, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Biomarin Pharmaceutical's net margin excels beyond industry benchmarks, reaching 6.95%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Biomarin Pharmaceutical's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 0.83%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.61%, the company showcases effective utilization of assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.22.
The Significance of Analyst Ratings Explained
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
